GH secretagogues and sleep: separating signal from bro-science

What did @dereklifts2 actually say?

The creator laid out four "pivots" for researchers experiencing sleep disruption from GH secretagogues. The core argument: secretagogues exist on a spectrum from "broad and aggressive" to "narrow and selective," and the broader ones, specifically GHRP-2, GHRP-6, and Hexarelin, carry more risk for sleep interference than something like ipamorelin. He also argued that timing matters, that morning dosing may sidestep nighttime disruption, and that stacking a GHRH with a GHRP is not always necessary.

He specifically claimed ipamorelin "targets that GH pulse with the least amount of cortisol and prolactin increase" and that GHRP-6 causes significant hunger increases that ipamorelin avoids. He framed all of this as what "the science says." That framing deserves scrutiny.

Does the science back this up?

Partially, yes. The receptor pharmacology argument is the strongest part of this video. The weaker parts involve overstating how clean ipamorelin really is and the claim that a GHRH alone is a reasonable standalone protocol for GH optimization.

GHRP-2, GHRP-6, and Hexarelin are all ghrelin receptor (GHSR-1a) agonists, but they also have meaningful off-target activity. GHRP-6 and GHRP-2 significantly elevate ACTH and cortisol in human studies (Arvat et al., 1998, Journal of Clinical Endocrinology and Metabolism). Hexarelin has the most pronounced cortisol and prolactin stimulation of the three (Ghigo et al., 1994, Journal of Endocrinological Investigation). Ipamorelin, by contrast, was specifically engineered for selectivity. Raun et al. (1998, European Journal of Endocrinology) demonstrated that ipamorelin produced robust GH release with minimal cortisol or prolactin elevation in rats and swine. That finding has held up in the limited human data available. So the selectivity argument is real, not invented.

The timing logic, specifically that morning cortisol peaks make aggressive secretagogues more contextually appropriate in the AM, is biologically plausible but not directly studied for this application. It is reasonable inference, not established protocol.

What did they get wrong (or right)?

They got the receptor selectivity framework right. That is legitimate pharmacology. The claim that ipamorelin causes the "least amount of cortisol and prolactin increase" among GHRPs is supported by the literature, not just bro-science.

What is shakier: the assertion that a GHRH like CJC-1295 or Tesamorelin used alone is a reasonable swap for a GHRP-GHRH stack. GHRHs and GHRPs work through entirely different mechanisms, GHRH amplifies the GH pulse, GHRPs increase pulse frequency and magnitude via ghrelin receptors. They are not interchangeable. Using CJC-1295 alone does produce GH elevation (Ionescu and Frohman, 2006, Endocrine Reviews), but the magnitude and pattern differ substantially from a stack. Calling it a simple pivot glosses over that distinction.

The hunger claim about GHRP-6 is accurate. GHRP-6 activates ghrelin pathways that directly stimulate appetite centers in the hypothalamus. This is well-documented and ipamorelin does not replicate it to the same degree.

What is missing entirely: any discussion of individual variation in GH axis sensitivity, age-related differences, or the fact that some sleep disruption from secretagogues may reflect GH itself increasing slow-wave sleep architecture in ways that feel disruptive initially (Van Cauter et al., 2000, JAMA).

What should you actually know?

Sleep disruption from GH secretagogues is real and documented, but the mechanism matters. It is not always a sign something is wrong. GH has a bidirectional relationship with slow-wave sleep. Increasing GH pulse amplitude can temporarily alter sleep architecture before the body adapts. That context is absent from this video.

The four-pivot framework the creator offers is not unreasonable as a general approach, but it treats these compounds as interchangeable tools when they are not. GHRP-6 and ipamorelin are not just different intensities of the same thing. They activate overlapping but distinct receptor profiles with different downstream effects beyond the GH axis.

None of these peptides, including ipamorelin and CJC-1295, are FDA-approved for the uses discussed here. Tesamorelin (Egrifta) is FDA-approved specifically for HIV-associated lipodystrophy, not general GH optimization. Using the name "Tesamorelin" in a general optimization context implies equivalency to compounded versions, which is not accurate and should not be assumed.

If you are experiencing sleep disruption during any peptide protocol, that is a signal worth discussing with a licensed clinician, not troubleshooting through a TikTok comment section.